Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
22 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01742299 | Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator | completed | Phase 4 | 155 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 18, 2026 | clinicaltrials |
| NCT04877522 | Asciminib Roll-over Study | recruiting | Phase 4 | 347 | Novartis PharmaceuticalsINDUSTRY | 29 | Jul 6, 2026 | clinicaltrials |
| NCT06440629 | Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)(RA-DRUM) | active not recruiting | Phase 4 | 387 | Diakonhjemmet HospitalOTHER | 6 | Jul 1, 2026 | clinicaltrials |
| NCT01909934 | Study of Brentuximab Vedotin in Participants With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma | completed | Phase 4 | 50 | TakedaINDUSTRY | 10 | Sep 19, 2025 | clinicaltrials |
| NCT01896479 | A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer(EXAMINER) | active not recruiting | Phase 4 | 247 | ExelixisINDUSTRY | 14 | Sep 2, 2025 | clinicaltrials |
| NCT04078152 | Durvalumab Long-Term Safety and Efficacy Study(WAVE) | completed | Phase 4 | 163 | AstraZenecaINDUSTRY | 31 | Dec 20, 2024 | clinicaltrials |
| NCT01794793 | Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies | completed | Phase 4 | 337 | RECORDATI GROUPINDUSTRY | 28 | Oct 1, 2024 | clinicaltrials |
| NCT02869789 | An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers | completed | Phase 4 | 1,041 | Bristol-Myers SquibbINDUSTRY | 21 | Jun 15, 2023 | clinicaltrials |
| NCT01957176 | A Rollover Study to Provide Continued Treatment With Eltrombopag | completed | Phase 4 | 22 | Novartis PharmaceuticalsINDUSTRY | 12 | Dec 30, 2022 | clinicaltrials |
| NCT01739764 | An Extension (Rollover) Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Malignancies Previously Enrolled in an Antecedent Vemurafenib Protocol | completed | Phase 4 | 215 | Hoffmann-La RocheINDUSTRY | 25 | Jan 7, 2021 | clinicaltrials |
| NCT01588184 | An Extension Study to Provide Continued Bevacizumab Therapy to Participants With Solid Tumors Who Were Previously Enrolled in a Roche/Genentech Sponsored Study | completed | Phase 4 | 95 | Hoffmann-La RocheINDUSTRY | 21 | Nov 5, 2020 | clinicaltrials |
| NCT01525550 | A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors | completed | Phase 4 | 106 | PfizerINDUSTRY | 15 | Jul 30, 2019 | clinicaltrials |
| NCT02500641 | Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout(FORWARD) | completed | Phase 4 | 196 | Menarini International Operations Luxembourg SAINDUSTRY | 6 | Jun 21, 2019 | clinicaltrials |
| NCT01180049 | Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma | completed | Phase 4 | 101 | PfizerINDUSTRY | 11 | May 20, 2019 | clinicaltrials |
| NCT02208843 | Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation | completed | Phase 4 | 60 | Boehringer IngelheimINDUSTRY | 7 | Dec 17, 2018 | clinicaltrials |
| NCT00430352 | MAXIMA Study: A Study of Maintenance Therapy With MabThera (Rituximab) in Patients With Non-Hodgkin's Lymphoma. | completed | Phase 4 | 545 | Hoffmann-La RocheINDUSTRY | 24 | Aug 14, 2017 | clinicaltrials |
| NCT01061177 | Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase('MACS1252) | completed | Phase 4 | 1,090 | Novartis PharmaceuticalsINDUSTRY | 26 | Feb 24, 2017 | clinicaltrials |
| NCT01203917 | Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC(IFUM) | completed | Phase 4 | 1,060 | AstraZenecaINDUSTRY | 13 | Jan 2, 2017 | clinicaltrials |
| NCT00949910 | An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) | completed | Phase 4 | 6,586 | Hoffmann-La RocheINDUSTRY | 51 | Oct 5, 2016 | clinicaltrials |
| NCT00451906 | A Study of Avastin (Bevacizumab) in Combination With Platinum-Containing Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Cell Lung Cancer. | completed | Phase 4 | 2,252 | Hoffmann-La RocheINDUSTRY | 40 | May 24, 2016 | clinicaltrials |
| NCT02372357 | A New Dosing Regimen for Posaconazole Prophylaxis in Children Based on Body Surface Area | completed | Phase 4 | 14 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Mar 3, 2015 | clinicaltrials |
| NCT00090038 | Effect of Rituximab on Immunological Recall Response to Specific Antigens in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 4 | 168 | BiogenINDUSTRY | 11 | Oct 20, 2009 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials